Amidst the ongoing global outbreak of mpox, previously known as monkeypox, Emergent BioSolutions Inc. takes a significant step forward in combating this public health threat. The World Health Organization (WHO) declared the current mpox outbreak a global Public Health Emergency of International Concern (PHEIC) on August 14, 2024, marking the second such declaration in two years. In response, Emergent BioSolutions published a groundbreaking review article titled ‘Brincidofovir in the Era of Mpox’ in the esteemed journal Expert Review of Anti-infective Therapy.
This article delves into the potential of brincidofovir as a treatment for mpox, providing in-depth analysis of in vitro and in vivo data, including human case studies. The company’s Chief Medical Officer, Dr. Simon Lowry, emphasizes the importance of advancing research on this global disease, highlighting the need for innovative therapeutic solutions. As part of these efforts, brincidofovir is currently undergoing evaluation in clinical trials, offering hope for patients battling mpox. Through collaborations with organizations like the Africa CDC and PANTHER, Emergent BioSolutions is at the forefront of the fight against mpox, showcasing its commitment to protecting and saving lives. For more information on Emergent BioSolutions’ groundbreaking work in the field of infectious diseases, visit their website and follow them on social media platforms for the latest updates.
Read more from finance.yahoo.com